Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

PROSCA/BLADDR 2023

29 Nov–02 December 2023 | Malaga, Spain

PROSCA/BLADDR 2023

29 Nov–02 December 2023 | Malaga, Spain
Positive surgical margins after RC for MIBC: what’s next? 1:30
Positive surgical margins after RC for MIBC: what’s next?
Paul Sargos • 4 Dec 2023
Overcoming challenges in localized bladder cancer management via biomarkers 1:25
Overcoming challenges in localized bladder cancer management via biomarkers
Paul Sargos • 4 Dec 2023
The future management of a T2N0M0 Uca from the radiation oncologist’s perspective 1:12
The future management of a T2N0M0 Uca from the radiation oncologist’s perspective
Paul Sargos • 4 Dec 2023
The evolving landscape of precision medicine & the role of molecular profiling in guiding therapies 7:32
The evolving landscape of precision medicine & the role of molecular profiling in guiding therapies
Bram De Laere • 5 Dec 2023
Trimodal therapy for MIBC: debates and innovations in radiation oncology 1:37
Trimodal therapy for MIBC: debates and innovations in radiation oncology
Paul Sargos • 4 Dec 2023
Liquid biopsy vs tissue biopsy in oncology 2:12
Liquid biopsy vs tissue biopsy in oncology
Bram De Laere • 5 Dec 2023
ProBio: a biomarker driven study in patients with metastatic prostate cancer 3:54
ProBio: a biomarker driven study in patients with metastatic prostate cancer
Bram De Laere • 5 Dec 2023
Challenges in the clinical adoption of liquid biopsy 2:53
Challenges in the clinical adoption of liquid biopsy
Bram De Laere • 5 Dec 2023
Managing toxicities in advanced urothelial cancers: insights on EV and erdafitinib 9:49
Managing toxicities in advanced urothelial cancers: insights on EV and erdafitinib
Rob Jones • 6 Dec 2023
The future of non-muscular invasive bladder cancer management 1:45
The future of non-muscular invasive bladder cancer management
Felix Guerrero-Ramos • 21 Oct 2023
High-risk, BCG-unresponsive NMIBC beyond RC: intravesical and systemic therapies 3:04
High-risk, BCG-unresponsive NMIBC beyond RC: intravesical and systemic therapies
Felix Guerrero-Ramos • 21 Nov 2023
Risk stratification in NMIBC: are we really doing it the right way? 2:12
Risk stratification in NMIBC: are we really doing it the right way?
Felix Guerrero-Ramos • 21 Nov 2023
Challenges in staging urinary tract tumors 2:58
Challenges in staging urinary tract tumors
Eva Compérat • 21 Nov 2023
Unraveling grading challenges in bladder tumors 2:41
Unraveling grading challenges in bladder tumors
Eva Compérat • 21 Nov 2023
Challenges in classifying bladder tumors: insights on heterogeneity and precision 5:03
Challenges in classifying bladder tumors: insights on heterogeneity and precision
Eva Compérat • 21 Nov 2023
The content of VJOncology is intended for healthcare professionals